article
Issue #5 2014 – Digital edition
In this issue: Protein Characterisation, RMM, Flow Cytometry, Spray drying, NMR spectroscopy, Raman, Pharmaceutical salts, Sterile Control Strategies and much more...
List view / Grid view
Drug delivery
news
Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline
3 November 2014 | By Auspherix Pty Ltd
Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further with AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies...
news
Micro Droplet Systems provide seamless production of monodispersed droplets
9 October 2014 | By kdm communications
Dolomite Microfluidics, a sister company to flow chemistry specialist Syrris, has developed an innovative range of Micro Droplet Systems for automatic, seamless production of monodispersed droplets...
news
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC
6 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor...
news
Small molecule antibodies for cancer immunotherapy: ImmuSmol raises 500 000 euros for in vivo proof-of concept
23 September 2014 | By ImmuSmol
ImmuSmol is announcing it has raised 500 000 euros to progress its cancer immunotherapy program to in vivo proof-of-concept...
news
Domain Therapeutics appoints Professor Michel Bouvier as chairman of the Scientific Advisory Board
22 September 2014 | By Domain Therapeutics
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs...
news
Nanoparticle synthesis benefits from award-winning Syrris batch and flow reactors
22 September 2014 | By kdm communications
Innovative batch and flow reactors from leading manufacturer Syrris are proving advantageous for a variety of nanoparticle applications, offering scientists working in the field numerous benefits...
article
Issue #4 2014 – Digital edition
In Issue #4 2014: Protein Expression, Multivariate Data Analysis, Informatics in-depth focus, Particle Sizing, Lean Manufacturing, NIR In-depth focus, X-Ray Fluorescence and much more...
article
Particle characterisation in drug delivery
5 September 2014 | By Driton Vllasaliu and Ishwar Singh, University of Lincoln
The use of materials in nano-scale dimensions is proving to be a promising approach to overcome drug delivery challenges. ‘Nanomedicine’ technologies are gradually achieving commercial success and reaching the clinic. Sub-micron nanocarriers have the potential to ferry the therapeutic to its site of action and in this process overcome the…
news
Prime Minister warns of global threat of antibiotic resistance
3 July 2014 | By Department of Health
The Prime Minister David Cameron called for global action to tackle the growing threat of resistance to antibiotics...
article
Issue #3 2014 – Digital edition
In Issue #3 2014: Pharmaceutical freeze-drying, Self-amplifying mRNA vaccines, Polymorph myths, Microbiology focus, NMR for isotope profiling, Manufacturing with QbD 2.0, Single-cell mRNA-Sequencing, qPCR focus, Powder Flow...
news
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
article
Issue #2 2014 – Digital edition
In Issue #2 2014: Mass Spectrometry and Stem Cells in-depth focuses, Hot Melt Extrusion, PAT, Excipients, Microbiology plus much more...
article
Issue #1 2014 – Digital edition
In Issue #1 2014: Raman Spectroscopy in-depth focus, Ingredients, LIMS, Kinase, Near Infrared in-depth focus, RNA, Microbiology...
news
Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…
